Assay sensitivity and the epistemic contexts of clinical trials

Perspectives in Biology and Medicine

Volumn 56, Issue 1, 2013, Pages 1-17

  Phillips Hey, Spencer ^a   Weijer, Charles ^b  

^a MCGILL UNIVERSITY   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); KNOWLEDGE; METHODOLOGY; RESEARCH ETHICS; SENSITIVITY AND SPECIFICITY;

CLINICAL TRIALS AS TOPIC; ETHICS, RESEARCH; KNOWLEDGE; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY;

EID: 84878690911     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.2013.0002     Document Type: Article

References (29)

1. Anderson, J.A. 2006.The ethics and science of placebo-controlled trials:Assay sensitivity and the Duhem-Quine thesis. J Med Philos 31:65-81.
2. Begg C. B., et al. 1996. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 276:637-39.
3. Duhem, P. 1962. The aim and structure of physical theory. Princeton: Princeton Univ. Press.
4. Fergusson, D., et al. 2009.Turning a blind eye:The success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ 328:432-34.
5. Freedman, B. 1987. Equipoise and the ethics of clinical research. New Engl J Med 317: 141-45.
6. Freedman, B. 1990. Placebo-controlled trials and the logic of clinical purpose. Hastings Cent Rep 12:1-6.
7. Friedman, L. M., C. D. Furberg, and D. L. DeMets. 1998. Fundamentals of clinical trials, 3rd ed. NewYork: Springer.
8. Fuks A., et al. 1998. A study in contrasts: Eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. J Clin Epidemiol 51:69-79.
9. Gelfand, L.A., et al. 2006. Bias resulting from the use of 'assay sensitivity' as an inclusion criterion for meta-analysis. Stat Med 25:943-55.
10. Hill,A. 1963. Medical ethics and controlled trials. BMJ 1:1043-49.
11. Howick, J. 2009. Questioning the methodologic superiority of "placebo" over "active" controlled trials. Am J Bioethics 9:34-48.
12. Hwang, I. K., and T. Morikawa. 1999. Design issues in noninferiority/equivalence trials. Drug Info J 33:1205-18.
13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH E10). 2000. Choice of control group and related issues in clinical trials E10. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf.
14. Kimmelman, J., C. Weijer, and E. M. Meslin. 2009. Helsinki discords: FDA, ethics, and international drug trials. Lancet 373:13-14.
15. Kirschner, N., S. G. Pauker, and J.W. Stubbs. 2008. Information on cost-effectiveness:An essential product of a national comparative effectiveness program. Ann Intern Med 148: 956-61.
16. Mayr, E. 1982. The growth of biological thought: Diversity, evolution, and inheritance. Cambridge: Belknap Press.
17. Moher, D., K. F. Schulz, and D. G. Altman. 2001.The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191-94.
18. Sampson, H., C. Weijer, and D. Pullman.2009.Research governance lessons from the National Placebo Initiative. Health Law Rev 17:26-32.
19. Schwartz, D., and J. Lellouch. 1967. Explanatory and pragmatic attitudes in therapeutical trials. J Chron Dis 20:637-48.
20. Shapiro, A. K. 1970. Placebo effects in psychotherapy and psychoanalysis. J Clin Pharamcol 10:73-78.
21. Shapiro, S., D. Fergusson, and K. Glass. 2010. Substituting placebo for established, effective therapy: Why not? CMAJ 182:1749-53.
22. Spiro, H. M. 1986. Doctors, patients, and placebos. New Haven:Yale Univ. Press.
23. Temple R., and S. S. Ellenberg. 2000. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med 133:455-63.
24. Thorpe, K. E., et al. 2009. A pragmatic-explanatory continuum indicator summary (PRECIS):A tool to help trial designers. J Clin Epidemiol 62:464-75.
25. U.S. Code of Federal Regulations. 2009.Title 21,Volume 7, §601.2.
26. Wimsatt, W. C. 2007. Re-engineering philosophy for limited beings: Piecewise approximations to reality. Cambridge: Harvard Univ. Press.
27. World Medical Organization (WMA). 1964. Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects. BMJ 313:1448-49.
28. World Medical Association (WMA). 2008. Declaration of Helsinki: Ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html.
29. World Medical Association (WMA). 2010. WMA Secretary General's report to 185th Council. World Med J 65:87-96.